Activation of GLP-1 Receptor Enhances Neuronal Base Excision Repair via PI3K-AKT-Induced Expression of Apurinic/Apyrimidinic Endonuclease 1
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is an intestinal-secreted incretin that increases cellular glucose up-take to decrease blood sugar. Recent studies, however, suggest that the function of GLP-1 is not only to decrease blood sugar, but also acts as a neurotrophic factor that plays a role in neuronal survival, neurite outgrowth, and protects synaptic plasticity and memory formation from effects of β-amyloid. Oxidative DNA damage occurs during normal neuron-activity and in many neurological diseases. Our study describes how GLP-1 affected the ability of neurons to ameliorate oxidative DNA damage. We show that activation of GLP-1 receptor (GLP-1R) protect cortical neurons from menadione induced oxidative DNA damage via a signaling pathway involving enhanced DNA repair. GLP-1 stimulates DNA repair by activating the cyclic AMP response element binding protein (CREB) which, consequently, induces the expression of apurinic/apyrimidinic endonuclease 1 (APE1), a key enzyme in the base excision DNA repair (BER) pathway. In this study, APE1 expression was down-regulated as a consequence phosphatidylinositol-3 kinase (PI3K) suppression by the inhibitor LY294002, but not by the suppression of MEK activity. Ischemic stroke is typically caused by overwhelming oxidative-stress in brain cells. Administration of exentin-4, an analogue of GLP-1, efficiently enhanced DNA repair in brain cells of ischemic stroke rats. Our study suggests that a new function of GLP-1 is to elevate DNA repair by inducing the expression of the DNA repair protein APE1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
γH2AX: a sensitive molecular marker of DNA damage and repair
Mah, L.-J., El-Osta, A., & Karagiannis, T. C. (2010) · Leukemia · doi:10.1038/leu.2010.6 · Cited by 1,557
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
DNA damage and its links to neurodegeneration
Madabhushi, R., Pan, L., & Tsai, L.-H. (2014) · Neuron · doi:10.1016/j.neuron.2014.06.034 · Cited by 654
Glutamate and Neurotrophic Factors in Neuronal Plasticity and Disease
Mattson, M. P. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1418.005 · Cited by 640 · cited 1×
“Accumulating evidence suggests GLP-1 is not only an incretin, but also has a neurotransmitter role [54-57].”
BackgroundExon duplication and divergence in the human preproglucagon gene
Bell, G. I., Sanchez-Pescador, R., Laybourn, P. J., & Najarian, R. C. (1983) · Nature · doi:10.1038/304368a0 · Cited by 593
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 4×
“Many studies have revealed that GLP-1[32,44], EX-4 [45-47], and other agonists of GLP-1R [40,48] have a neuroprotective role against neurodegenerative cell death, traumatic brain injury, and ischemic stroke.”
BackgroundInfluentialProtection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380 · cited 1×
“Current data indicate that GLP-1 not only regulates blood-sugar, but also has a role in neuroprotection, including protecting cells from excitotoxic neuronal damage [23], alleviating tau-hyperphosphorylation [24] and Aβ deposition and plaque formation [25], and reducing ischemia-induced brain damage [26-28].”
BackgroundWeissman, L., Jo, D.-G., Sorensen, M. M., de Souza-Pinto, N. C., Markesbery, W. R., Mattson, M. P., & Bohr, V. A. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm605 · Cited by 299
Yang, J.-L., Lin, Y.-T., Chuang, P.-C., Bohr, V. A., & Mattson, M. P. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8270-x · Cited by 159
Self-citation
Cited by
Zeng, Y., Du, W. W., Wu, Y., Yang, Z., Awan, F. M., Li, X., Yang, W., Zhang, C., Yang, Q., Yee, A., et al. (2017) · Theranostics · doi:10.7150/thno.19764 · Cited by 403
Self-citationPleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“GLP-1’s oxidative stress protective mechanisms are indicated to be ameliorated in primary cortical neurons by GLP-1/CREB signaling inducing expression of apurinic/apryimidinic endonuclease 1 (APE1), a key enzyme of the base excision DNA repair (BER) pathway (333), while also impacting protein aggregation induced neuro…”
BackgroundKopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Li, P., Stetler, R. A., Leak, R. K., Shi, Y., Li, Y., Yu, W., Bennett, M. V. L., & Chen, J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.011 · Cited by 256
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Liu, J., Wang, F., Liu, S., Du, J., Hu, X., Xiong, J., Fang, R., Chen, W., & Sun, J. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.08.3235 · Cited by 218
Self-citationGLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Wilbon, S. S., & Kolonin, M. G. (2023) · Cells · doi:10.3390/cells13010065 · Cited by 101
Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents
Gurjar, A. A., Kushwaha, S., Chattopadhyay, S., Das, N., Pal, S., China, S. P., Kumar, H., Trivedi, A. K., Guha, R., Chattopadhyay, N., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2019.154044 · Cited by 79
Yang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
Maskery, M. P., Holscher, C., Jones, S. P., Price, C. I., Strain, W. D., Watkins, C. L., Werring, D. J., & Emsley, H. C. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20952011 · Cited by 51
“Additional research is required to fully understand the role of cleaved GLP-1 subunits, including GLP-1 [28-36] and could go some way to explain the difference in stroke reduction between GLP-1RAs in CVOTs.”
BackgroundZeng, S.-S., Bai, J.-J., Jiang, H., Zhu, J.-J., Fu, C.-C., He, M.-Z., Zhu, J.-H., Chen, S.-Q., Li, P.-J., Fu, X.-Q., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00585 · Cited by 35
“…system, such as Alzheimer’s disease (McClean et al., 2011; McClean and Hölscher, 2014), Parkinson’s disease (Aviles-Olmos et al., 2014; Badawi et al., 2017), acute ischemic stroke (Yang et al., 2016; Dong et al., 2017), and traumatic brain injury (DellaValle et al., 2014; Hakon et al., 2015).”
BackgroundSelf-citationUnlocking Longevity with GLP-1: A Key to Turn Back the Clock?
Chavda, V. P., Balar, P. C., Vaghela, D. A., & Dodiya, P. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108028 · Cited by 24
Noguchi, T., Katoh, H., Nomura, S., Okada, K., & Watanabe, M. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1342944 · Cited by 20
Metadata
- Authors
- Yang, J.-L., Chen, W.-Y., Chen, Y.-P., Kuo, C.-Y., & Chen, S.-D.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2016
- Volume
- 6
- Issue
- 12
- Pages
- 2015-2027
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2520005058
- Cited by
- 74
- References
- 13
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.